Tinidazole is a drug used against protozoan infections. It is widely known throughout Europe and the developing world as a treatment for a variety of amoebic and parasitic infections. It was developed in 1972 and is a prominent member of the nitroimidazole antibiotic class.
|Trade names||Fasigyn, Simplotan, Tindamax|
|Elimination half-life||12–14 hours|
|Excretion||Urine (20–25%), faeces (12%)|
|CompTox Dashboard (EPA)|
|ECHA InfoCard||100.039.089 |
|Chemical and physical data|
|Molar mass||247.273 g/mol g·mol−1|
|3D model (JSmol)|
Tinidazole is marketed by Mission Pharmacal under the brand name Tindamax, by Pfizer under the names Fasigyn and Simplotan, and in some Asian countries as Sporinex.
A large body of clinical data exists to support use of tinidazole for infections from amoebae, giardia, and trichomonas, just like metronidazole. Tinidazole may be a therapeutic alternative in the setting of metronidazole intolerance. Tinidazole may also be used to treat a variety of other bacterial infections (e.g., as part of combination therapy for Helicobacter pylori eradication protocols).
Drinking alcohol while taking tinidazole causes an unpleasant disulfiram-like reaction, which includes nausea, vomiting, headache, increased blood pressure, flushing, and shortness of breath.
Elimination half-life is 13.2 ± 1.4 hours. Plasma half-life is 12 to 14 hours.
- Ebel, K., Koehler, H., Gamer, A. O., & Jäckh, R. “Imidazole and Derivatives.” In Ullmann’s Encyclopedia of Industrial Chemistry; 2002 Wiley-VCH, doi:10.1002/14356007.a13_661
- Edwards, David I. "Nitroimidazole drugs – action and resistance mechanisms. I. Mechanism of action" Journal of Antimicrobial Chemotherapy 1993, volume 31, pp. 9–20. doi:10.1093/jac/31.1.9.